NKGen Biotech ( (NKGN) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NKGen Biotech, Inc. has announced a delay in filing its Annual Report on Form 10-K (Yearly Report) for the fiscal year ending December 31, 2024. The delay is primarily due to the timing of management’s first public year-end close process and related administrative matters, which could not be resolved without unreasonable effort or expense. The company expects to file the report within the fifteen-day grace period allowed by Rule 12b-25. NKGen Biotech does not anticipate any significant changes in its financial results compared to the previous fiscal year. The notification was signed by Paul Song, the Chief Executive Officer, indicating ongoing compliance efforts.
More about NKGen Biotech
YTD Price Performance: -76.41%
Average Trading Volume: 3,985,220
Technical Sentiment Signal: Buy
Current Market Cap: $7.34M
See more data about NKGN stock on TipRanks’ Stock Analysis page.